Lab
Vpa PC
Vpa PC was paid $8.08M by Medicaid between Jan 2018 and Dec 2024, across 86 billing codes. Its largest line is 83970, — 9.2% of everything it billed.
33Billing provider infoVPA PC
TROY, MI 48084
TROY, MI 48084
33aNPI1427120336assigned 11/15/2006
33bProvider typeClinical Medical Laboratory
28Total paid$8.08M
24GClaims1,087,078
24DCodes billed86
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Michigan
Rank by total paid#14 of 108
Median peer was paid$588K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official STEVENS, JEFFREY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 160,767 | $1.26M | |
| 2019 | 199,593 | $1.59M | |
| 2020 | 172,260 | $1.12M | |
| 2021 | 171,113 | $1.21M | |
| 2022 | 160,999 | $1.19M | |
| 2023 | 145,275 | $1.11M | |
| 2024incomplete | 77,071 | $601K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 83970 | 9.2% | 34,484 | 32,147 | $747K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 8.4% | 41,342 | 37,708 | $679K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 7.4% | 4,987 | 3,990 | $602K |
| 82607 | 5.8% | 58,722 | 53,855 | $471K | |
| 84443 | Thyroid stimulating hormone (TSH) | 5.6% | 54,131 | 49,010 | $452K |
| 84134 | 5.4% | 58,888 | 54,396 | $433K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.3% | 15,286 | 14,287 | $431K |
| 80053 | Comprehensive metabolic panel | 5.2% | 78,915 | 72,367 | $423K |
| 82746 | 4.9% | 51,505 | 47,111 | $396K | |
| 83880 | 4.6% | 19,665 | 18,183 | $375K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 4.4% | 62,437 | 58,417 | $353K |
| 83721 | 3.8% | 54,692 | 50,536 | $309K |
74 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.7% | 74,853 | $295K |
| 83718 | 2.9% | 52,298 | $238K | |
| 80050 | General health panel | 2.5% | 11,898 | $205K |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 1.8% | 77,049 | $146K |
| 83735 | 1.4% | 34,444 | $116K | |
| 84439 | 1.3% | 23,135 | $108K | |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 72,566 | $90K |
| 87482 | 1.1% | 4,177 | $90K | |
| 84550 | <1% | 31,387 | $77K | |
| 83090 | <1% | 8,324 | $77K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,055 | $72K |
| 82274 | <1% | 5,021 | $71K | |
| 87640 | <1% | 4,690 | $68K | |
| 87653 | <1% | 4,707 | $68K | |
| 84481 | <1% | 6,867 | $56K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 5,024 | $53K |
| 82728 | <1% | 8,194 | $52K | |
| 84100 | <1% | 19,103 | $46K | |
| 82043 | <1% | 10,111 | $36K | |
| 83550 | <1% | 7,903 | $32K | |
| 80074 | <1% | 973 | $29K | |
| 83540 | <1% | 9,038 | $29K | |
| 84153 | <1% | 2,605 | $29K | |
| 80061 | Lipid panel | <1% | 3,809 | $25K |
| 82570 | <1% | 8,024 | $24K | |
| 80164 | <1% | 2,722 | $22K | |
| 86800 | <1% | 2,996 | $22K | |
| 86376 | <1% | 3,038 | $20K | |
| 86430 | <1% | 4,656 | $18K | |
| 82248 | <1% | 6,218 | $18K | |
| 81001 | <1% | 10,136 | $17K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 916 | $16K |
| 86140 | <1% | 4,234 | $14K | |
| 87186 | <1% | 3,665 | $14K | |
| 86803 | <1% | 1,858 | $14K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 364 | $13K |
| 80377 | <1% | 3,657 | $12K | |
| 80177 | <1% | 1,625 | $11K | |
| 82523 | <1% | 1,026 | $9K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 244 | $9K |
| 85610 | <1% | 2,533 | $5K | |
| 87481 | <1% | 448 | $5K | |
| 80171 | <1% | 379 | $5K | |
| 82977 | <1% | 495 | $3K | |
| 85027 | <1% | 1,065 | $3K | |
| 82465 | <1% | 1,515 | $3K | |
| 82172 | <1% | 337 | $3K | |
| 83690 | <1% | 793 | $2K | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 1,932 | $2K |
| 82150 | <1% | 738 | $2K | |
| 82550 | <1% | 454 | $2K | |
| 80156 | <1% | 191 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,073 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 370 | $1K |
| 81003 | <1% | 1,115 | $1K | |
| 86141 | <1% | 165 | $1K | |
| 80185 | <1% | 162 | $1K | |
| 80376 | <1% | 272 | $1K | |
| 80178 | <1% | 227 | $1K | |
| 84152 | <1% | 84 | $898.03 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 175 | $710.11 |
| 84478 | <1% | 143 | $670.96 | |
| 81002 | <1% | 175 | $317.90 | |
| 84156 | <1% | 94 | $245.46 | |
| 85730 | <1% | 112 | $238.12 | |
| 87088 | <1% | 58 | $190.90 | |
| 86703 | <1% | 16 | $137.06 | |
| 80175 | <1% | 12 | $125.71 | |
| 87340 | <1% | 22 | $112.03 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 133 | $100.00 |
| 85045 | <1% | 42 | $78.06 | |
| 82565 | <1% | 29 | $67.58 | |
| 85651 | <1% | 21 | $46.63 | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTEVENS, JEFFREY (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Vpa PC | Troy, MI | $19.24M |
| Rmed LLC | Maitland, FL | $11.88M |
| Vpa PC | Middleburg Heights, OH | $4.58M |
| Vpa of Texas PLLC | Irving, TX | $4.20M |
| Vpa PC | Portage, MI | $4.09M |
| Vpa PC | Maumee, OH | $2.77M |
| Vpa PC | Moraine, OH | $2.32M |
| Vpa PC | Boardman, OH | $2.08M |
| Vpa PC | Renton, WA | $2.07M |
| Vpa PC | Brownsburg, IN | $1.97M |
| Vpa PC | Columbus, OH | $1.80M |
| Vpa PC | Columbus, OH | $1.28M |
| Vpa of Texas PLLC | San Antonio, TX | $1.24M |
| Vpa PC | Overland Park, KS | $1.23M |
| Vpa PC | West Allis, WI | $1.23M |
| Advantechs X-Ray Imaging Services, LLC | Irving, TX | $997K |
| Vpa PC | Brookfield, WI | $905K |
| Vpa PC | Tigard, OR | $858K |
| Vpa PC | Phoenix, AZ | $778K |
| Vpa PC | South Bend, IN | $746K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.